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Table 1. MPI values before and after recanalization of RCA CTO
Basal Early Late P1 P2 P3
2d MPI 0.610.09 0.600.08 0.530.07 0.84 <0.001 <0.001
TD septal MPI 0.580.09 0.570.07 0.530.08 0.33 0.003 <0.001
TD lateral MPI 0.590.08 0.580.08 0.510.07 0.42 <0.001 <0.001
P1: basal vs. earlyMPI, P2: basalvs. lateMPI, P3: early vs. lateMPI, valuesaremeanstd. deviation







SBackground: Successful CTO treatment is able to increase left ventricular function,
exercise capacity and reduction of mortality. Up to date no adequate information on
stent strut endothelialisation after CTO treatment is available. In particular, the
duration of dual antiplatelet therapy (DAPT) remains an issue of debate. Following
CTO treatment, patients are at risk for restenosis as well as stent thrombosis. DAPT is
able to sufﬁcient reduce frequency of stent thrombosis, but keeps an increased risk of
major bleeding in case of unnecessarily prolonged ingestion. Intracoronary optical
coherence tomography (OCT) is a novel invasive method, which is able to precisely
analyse stent strut endothelialisation. We tested the hypothesis, that OCT detects
delayed endothelialisation after CTO treatment compared to non-CTO PCI.
Methods: We performed diagnostic OCT measurements following successful CTO
treatment (n ¼ 22) as well as non-CTO DES PCI of complex lesions (n ¼ 29). All
Patients had been treated with 2nd generation DES. Mean time point of OCT analysis
was 7.8 months and 6.5 months, respectively (p ¼ 0.83).
Results: The two groups were well matched and similar concerning characteristics.
Stent struts (in total n ¼ 13629) were analysed and classiﬁed by OCT according to
previously described methods (CTO recanalization vs. non-CTO DES; mean +/- SEM):
covered struts: 81.65 +/- 2.9% vs. 97.34 +/- 0.78%, p<0.0001; protruding/uncovered
struts: 10.1 +/- 1.7% vs. 1.4 +/- 0.4%, p<0.0001; malapposed/uncovered struts: 7.9 +/-
2.0 % vs. 1.3 +/- 0.5 %, p<0.001. We performed subgroup analysis concerning CTO
recanalization by antegrade vs. retrograde approach as well as subintimal tracking vs.
non-subintimal tracking methods. No signiﬁcant differences were found concerning
subgroup analysis. No MACE events were detected in this series.
Conclusions: Here we describe delayed stent endothelialisation after CTO treatment.
Our results suggest an urgent need to extend the DAPT after CTO treatment to reduce
the risk of late stent thrombosis. OCT allows interventional cardiologists to safe and
precisely perform follow-up examinations in patients after CTO recanalization with
the ability of individualise the duration of DAPT.
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Background: Second-generation drug-eluting stents (DES) have reduced the occurrence
of target vessel revascularisation (TVR) and stent thrombosis compared to ﬁrst-generation
DES but the clinical impact in chronic total occlusion (CTO) is poorly described.We aimed
to compare long-term outcome after 1st and 2nd-generation DES in patients with CTO.
Methods: Of 1,343 consecutive Patients who underwent PCI for CTO between 2004 and
2012, long termoutcomewas evaluated after successful DES implantation.Major adverse
cardiac events (MACE) including cardiac death, target vessel revascularisation (TVR) and
myocardial infarction (MI) were compared between patients treated with 1st (sirolimus
and paclitaxel) and 2nd -generation DES (everolimus, zotarolimus and biolimus).
Results: Procedural success was achieved in 1000 (74.4 %) patients of which 943
(70.2%) received at least one stent. DES were implanted in 873 patients (65%) who
deﬁned the study population.Patients treated with 1st generation DES (583 patients,
66.9% of the whole population) had a higher rate of current smoking (28% vs. 20%
p¼0.007), were more frequently treated for left anterior descending CTO (37% vs.
29% p¼0.018) and had shorter stent length (46  25 vs. 51  25 mm, p¼) compared
to patients treated by 2nd generation DES. Age, gender, diabetes, and LVEF were
similar between groups. Median follow-up was at 4.1 years (IQR: 2.4-6.5 years).
Patients treated 2nd generation DES had lower MACE rate compared to 1st-genera-
tion DES (12.7% vs. 21.3%, respectively, p¼0.003). The decrease in MACE rate was
driven by lower TVR (8.7%, vs. 13.4%, respectively p¼0.04) whereas cardiac death
and MI were similar between groups (p¼0.32 and p¼0.15, respectively). Cumulative
event rates by Kaplan-Meier analysis showed lower incidence of TVR among patients
treated by 2nd generation stent (p Log Rank ¼0.02).
Conclusions: In patients successfully treated by PCI for CTO, 2nd generation DES
are associated with better long-term clinical outcome, when compared to 1st gener-
ation DES. This is mainly driven by lower TVR rates
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Background: PCI of chronic total occlusion (CTO) has becomemore andmore aggressive
during the last decade, especially because of frequent use of hydrophilic, hard and stiffwires,
which have increased the rate of success. Indeed, the incidence and clinical consequences of
cardiac tamponade in contemporary practice remain relatively unknown.B118 JACC Vol 62/18S1/Suppl B j October 27–NMethods: Between October 2003 and June 2010, a total of 1509 consecutive patients
were treated by PCI for a CTO deﬁned as the presence of TIMI 0 ﬂowwithin an occluded
arterial segment of greater than 3 months standing. The population characteristics were
compared regarding the presence of per and post-procedural tamponade.
Results: A cardiac tamponade occurred in 18/1509 patients (1.2%). As opposed to
patients with a tamponade-free procedure, patients who have experienced cardiac
tamponade were older (68.610.34 vs. 63.411.29, p¼0.03) and had similar risk
factors (diabetes in 27% and dyslipidemia in 64%). Cardiac tamponade occurred more
frequently in experienced operators reﬂecting more complex procedures. Absence of
visible stump was associated with higher rate of cardiac tamponade (50% vs. 24.8% for
patients without tamponade, p¼0.02). There were no differences regarding other
angiographic characteristics between the two groups (calciﬁcations, proximal tortuosi-
ties, lesion length). The use of a tornus device and a retrograde approach were associated
with higher rates of cardiac tamponade (0.17vs 0.02 p¼0.01, and 0.28vs 0.01 p¼0.02,
respectively). Procedural duration was longer in patients in whom a cardiac tamponade
occurred (12424 minutes, vs. 9237 minutes, p¼0.01) and success rate was equal
(0.77 vs 0.70., p¼0.61, respectively). Importantly, in-hospital stay was longer (7.23.6,
vs. 3.13, p<0.0001, respectively), and rate of in-hospital death was higher among
patients who have experienced cardiac tamponade compared to those without per and
post-procedural tamponade (11% vs. 1%, p¼0.01, respectively).
Conclusions: Cardiac tamponade occurred in 1.2% of a broad population of consecutive
patients treated by PCI for chronic total coronary occlusion. Absence of visible stump and
use of aggressive devices and strategies were more frequently associate.
TCT-377
Myocardial Performance Index After Successful Recanalization of Chronic Total
Coronary Occlusions
Gulhan Y. Kalkan1, Oytun A. Baykan1, Zafer Elbasan1, Durmus Y. Sahin1,
Taner Seker1, Mustafa Gur1, Caner Turkoglu1, Murat Cayli1
1Adana Numune Training and Research Hospital, Adana, Turkey
Background: Percutaneous recanalization of chronic total coronary occlusions (CTO)
tends to show a positive effect on LV remodeling and ejection fraction (EF). Never-
theless, its effects on global cardiac functions are yet to be fully understood. Myocardial
performance index (MPI) is likely to be more effective for analysis of global cardiac
dysfunction than systolic and diastolic measures alone. The aim of this study was to
evaluate the effects of recanalization of CTO on global cardiac functions by using MPI.
Methods: We evaluated 25 patients (20 men, mean age 57.514.1 years) who had
ischemia on myocardial perfusion imaging and underwent successful percutaneous
coronary intervention of right coronary artery (RCA) CTO. All patients underwent
transthoracic echocardiography before (basal), 24 hours after (early) and at third
months (late) of successful PCI. The MPI was calculated by using pulse wave tissue
Doppler (TD) echocardiography.
Results: There was no difference between basal, early and late left ventricular ejection
fraction values (53.510.2, 53.39.5, 53.311.2, respectively). The MPI at third
month was signiﬁcantly increased compared to the basal and early MPI (0.610.09 vs.
0.530.07; p <0.001 and 0.600.08 vs. 0.530.07; p<0.001, respectively). On the
other hand, there was no signiﬁcant difference between basal and early MPI (0.610.09
vs. 0.600.08; p¼0.84, respectively). Also, TDMPI within 3 months was signiﬁcantly
increased when compared to others (0.580.9 vs. 0.530.8; p¼0.003, 0.570.07 vs.
0.530.8; p<0.001, respectively for TD MPI septal and 0.590.08 vs. 0.510.07;
p<0.001, 0.580.08 vs. 0.510.07; p<0.001, respectively for TD MPI lateral).Conclusions: In this study, we have shown that successful recanalization of CTO
results in increased MPI-indicated global cardiac functions within 3 months, while the
EF values remain unchanged.
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Background: New generation drug eluting stents (DES) signiﬁcantly improved short-
and long-term vessel patency after CTO recanalization. Data on the performance ofovember 1, 2013 j TCT Abstracts/POSTER/Chronic Total Occlusions







SDES with bioresorbable polymer in this setting are limited and therefore the
NOBORI-CTO registries were conducted.
Methods: In 2 large, prospective, multi-center registries, 504 out of 14134 patients
treated with Nobori DES had at least one CTO lesion revascularized. All adverse
events were adjudicated by an independent clinical event committee. The primary
endpoint was Target Lesion Failure (TLF) at 1 year.
Results: CTOpatientswere 6011 years old, 82.9%males, having priorMI, prior PCI and
previous cardiac surgery in 46.9%, 27.9% and 6.4% of patients. Multiple vessels were
treated in 35.5% of patients (2.161.40 lesions per patient) with an average 1.490.77
stents per lesion. Antegrade approach and single wire techniquewere most frequent choice.
Other techniques used included CTO dedicated wires, OTW balloon, microcatheter, rota-
tional atherectomy and cutting balloon. Mean diameter stenosis before procedure was
9116% and TIMI 0 and 1were recorded in 59% of the all lesions treated (not all were
CTO).Mean ﬂuoro timewas 3738minutes and contrast volumewas 276135mL. After
proceduremean diameter stenosis was 717%andTIMI 0 and 1were observed in only 3%
of the lesions. Up to 1-month, there was 1death, 3MIs (0.6%) and no TLR. Four CD (1.2%)
and three TLRs (0.9%)were reported up to one year follow-upbringing the total TLF rate to
2.4%. Target vessels non-target lesion revascularizations were performed in 2 patients
(0.6%). Only one probable subacute stent thrombosis (0.2%) occurred. In the cohort of
patients followed at 3-year, 3 patients suffered a CD (3.1%), 1 had an MI (1.0%), 3
underwent TLR (3.1%) and TLF rate was 6.2% with no late or very late stent thrombosis.
Conclusions:Treatment ofCTOwithNoboriDESshowedexcellent outcomes. Particularly
appealing is that stent thrombosis was very rare despite the multiple overlapping stents. The
low rate of procedural complications and adverse events up to 3 years suggests that this stent
is a valuable treatment option for patients with CTOwho are considered candidates for PCI.
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Background: In-stent restenosis (ISR) chronic total occlusion (CTO) lesions have been
known to be themost challenging subsets for percutaneous coronary intervention among the
CTO population. There have been few reports about ISR CTO intervention. Therefore, we
compared the success rates and long-term outcomes after PCI between ISR and de novo
CTO lesions.
Methods: The data for 368 patients undergoing intervention for CTO from 1998 to
2008 were analyzed. We compared the target lesion revascularization (TLR) success
rate and 5-years follow up outcomes including major adverse cardiovascular and
cerebrovascular event (MACCE) between the patients underwent PCI for ISR CTO
(n¼40) and de novo CTO (n¼328) lesion. TLR success was deﬁned as recovery of
Thrombolysis in Myocardial Infarction (TIMI) grade 3 and residual stenosis diameter
below 30%.
Results: No signiﬁcant difference was observed in clinical and angiographic char-
acteristics excepting deployed stent length (20.822.9mm in ISR vs 31.925.7mm in
de novo group, p¼0.006) and used contrast dose (220.192.2ml in ISR vs
269.36111ml in de novo group, p¼0.003) between both groups. Success rate of
TLR was 80% of the ISR CTO group and 83.8% of de novo group (p¼0.50). In the
ISR CTO group, the success rate of re-stenosed drug eluting stent (DES) using
patients tended to be superior than that of re-stenosed bare metal stent (BMS) using
patients, but it's not signiﬁcant (85.7% vs 71.4%, p¼0.576). The 5-year MACCE-free
survival of ISR CTO group was signiﬁcantly lower than de novo group (61.6% vs
89.8%, p¼0.034). On multivariate analysis, ISR CTO was associated with higher
incidence of MACCE (hazard ratio 2.29, 95% conﬁdence interval 1.046 to 5.030).
Conclusions: Procedural success rate for ISR CTO lesion was similar to that of de
novo CTO lesion. But, ISR CTO group showed worse long term clinical prognosis
than de novo CTO group.
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Background: Up to 30% chronic total occlusions (CTO) cannot be revascularized by
conventional angioplasty. Therapeutic enhancement of the antegrade collateral
circulation may offer a novel solution. Previously, we investigated stimulation of
endothelial cell (EC) angiogenesis via stabilized hypoxia inducible factor (HIF)
utilizing two prolyl-hydroxylase inhibitors. We reported di-methyl oxalylglycine
(DMOG) increased collateral neovascularization in a porcine CTO model and showed
BIQ(FG-2216), trialled for use in man for alternative indications, induced a dose-
dependent pro-angiogenic response in primary human EC in vitro. We now report
molecular mechanisms underlying the novel action of BIQ.
Methods: Human umbilical vein ECs (HUVECs) were treated with 500mM BIQ for
up to 24 hours. (100mM CoCl2 was used as a positive control for HIF-1a stabiliza-
tion). Expression of HIF-1a protein from cell lysates was analyzed by WesternJACC Vol 62/18S1/Suppl B j October 27–November 1, 2013 j TCT Abblotting. Quantitative PCR was used to examine the expression of vascular endothelial
cell growth factor (VEGF) mRNA from treated EC.
Results: Stabilization of HIF-1a protein was demonstrated in EC after treatment with
BIQ, along with a 1.45 fold increase in VEGF mRNA expression, after one hour of
treatment (Figure).Conclusions: We have conﬁrmed that BIQ(FG-2216) upregulates HIF-1a in EC and
shown evidence for a mechanism involving the angiogenic factor VEGF; important if
we plan to translate this therapy. On-going work includes the deployment of polymer-
coated BIQ eluting stents with in vitro and in vivo evaluation to develop an effective
treatment for difﬁcult CTOs in man.
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Background: The hybrid approach to coronary chronic total occlusion (CTO)
crossing was developed to optimize procedural efﬁcacy, efﬁciency, and safety.
Methods: We examined the procedural techniques and outcomes of 287 consecutive
CTO cases performed using the hybrid approach between August 2011 and June 2013
at 4 US centers: Appleton Cardiology, Appleton Wisconsin; St. Joseph Medical
Center, Bellingham Washington; St. Luke's Health System's Mid-America Heart
Institute, Kansas City, Missouri; and VA North Texas Healthcare System, Dallas,
Texas.
Results:Mean age was 64.410.2 years and 89% of the patients were men, with high
prevalence of diabetes mellitus (45%), peripheral arterial disease (17%), prior
percutaneous coronary intervention (60%) and prior coronary artery bypass graft
surgery (36%). Most target CTOs were located in the right coronary artery (60%),
followed by the left anterior descending artery (21%), left circumﬂex (17%), posterior
descending artery (1%) and left main coronary artery (1%). Dual injection was used in
74%. Overall, antegrade wire escalation was used in 63%, antegrade dissection re-
entry in 38% and retrograde in 45%. Among successful cases, the ﬁnal successful
crossing technique was antegrade wire escalation in 41%, antegrade dissection an re-
entry in 27%, and retrograde in 32%. The initial crossing strategy was successful in
60% of the patients, whereas 33% required an additional 1 to 4 crossing strategies.
Technical success was achieved in 93% and major procedural complications occurred
in 2% (death in 2 patients, one due to tamponade and one due to vascular access
complication; and myocardial infarction in 3 patients). Mean contrast volume, ﬂuo-
roscopy time, and air kerma radiation exposure were 275.2149.0 ml, 45.930.7
minutes, and 3.872.25 Gray, respectively.
Conclusions: Application of the hybrid strategy to CTO crossing resulted in high
success and low complication rates among a varied operator group and hospital
structure, further supporting the value of the hybrid approach in crossing these
challenging coronary lesions.stracts/POSTER/Chronic Total Occlusions B119
